title: Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis.
abstract: OBJECTIVE
  
  
  
  METHODS
  with rheumatoid factor positive inflammatory polyarthritis (IP) are known to have increased mortality from cardiovascular disease (CVD). A study was undertaken to examine the risk and baseline predictors of admission with CVD in patients with recent-onset IP.
  
  
  METHODS
  Subjects are recruited by the Norfolk Arthritis Register if they present to primary or secondary care with > or =2 swollen joints lasting > or =4 weeks. This analysis includes subjects recruited between 1995 and 1999. Baseline data on lifestyle, demographic characteristics, disease and treatment characteristics were collected. CVD admissions were identified through record linkage with the only acute care hospital in the study region. First-episode hospitalisation rates were compared with those of the general population. Poisson regression was used to calculate the relative risk (RR) of admission for patients with IP (overall and for each risk factor). Death certificates were obtained from the national death register.
  
  
  RESULTS
  800 patients with recent-onset IP were followed for a median of 7.0 years. 64 CVD-related hospitalisations were observed (11.7 per 1000 person-years). Patients with IP were twice as likely (RR=2.0; 95% CI 1.5 to 2.5) to be hospitalised for CVD as the general population. Difficulty walking at baseline was a significant predictor of CVD admission and baseline non-steroidal anti-inflammatory drug use was associated with a reduced risk of CVD admission.
  
  
  CONCLUSIONS
  Patients with IP are at increased risk of CVD-related hospitalisation, within 7 years of symptom onset. Informing patients about lifestyle modification may reduce the risk of CVD.
authors.affiliation: arc Epidemiology Unit, Manchester Academic Health Sciences Centre, University of Manchester, Stopford Building, Oxford Road, Manchester, UK.
authors.forename: Jarrod
authors.initials: J
authors.lastname: Franklin
authors.forename: Tracey M
authors.initials: TM
authors.lastname: Farragher
authors.forename: Mark
authors.initials: M
authors.lastname: Lunt
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Camacho
authors.forename: Diane
authors.initials: D
authors.lastname: Bunn
authors.forename: Tarnya
authors.initials: T
authors.lastname: Marshall
authors.forename: Deborah P M
authors.initials: DP
authors.lastname: Symmons
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001168:Arthritis / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology*; D004363:Drug Utilization / Q000706:statistics & numerical data; D004739:England / Q000453:epidemiology; D004812:Epidemiologic Methods; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D016138:Walking
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents